The reverse mergers are flowing. Q32 Bio will take Homology Medicines’ place on the Nasdaq, the companies said Thursday morning, and the biologics maker expects to have about $115 million at the time their deal closes.
The Massachusetts biotechs follow Lenz Therapeutics and…
Click here to view original post
